药品开发、制造商US WorldMeds完成收购Adaptimmune的细胞治疗产品组合，确保患者持续获得Tecelra和推进lete-cel的发展-动脉网

US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio; Ensures Continued Patient Access to Tecelra and Advances Development of lete-cel

CISION 等信源发布 2025-08-05 04:00



可切换为仅中文







LOUISVILLE, Ky.

路易斯维尔，肯塔基州

，

Aug. 4, 2025

2025年8月4日

/PRNewswire/ -- US WorldMeds (USWM) reported the successful closing of the previously announced acquisition of Adaptimmune Therapeutics plc's (Adaptimmune) cell–therapy assets—including TECELRA

/PRNewswire/ -- 美国WorldMeds（USWM）宣布成功完成了此前宣布的对Adaptimmune Therapeutics plc（Adaptimmune）细胞疗法资产的收购，其中包括TECELRA。

(afamitresgene autoleucel), lete–cel, afami–cel, and uza–cel.

(afamitresgene autoleucel)，lete–cel，afami–cel，以及 uza–cel。

The acquisition was first announced on July 28, 2025

该收购交易于 2025 年 7 月 28 日首次宣布。

and has now been finalized.

并且现已最终确定。

Under the terms of the Asset Purchase Agreement, USWM paid

根据《资产购买协议》的条款，USWM 支付了

$55 million

5500万美元

in cash at closing and will fund up to an additional

在交割时以现金支付，并将提供额外的资金支持

$30 million

3000万美元

in performance-based milestone payments tied to commercial and regulatory outcomes. Adaptimmune has retained rights to its pre–clinical programs, including PRAME– and CD70–directed T–cell therapies, and its allogeneic pipeline.

基于与商业化和监管结果挂钩的绩效里程碑付款。Adaptimmune保留了其临床前项目（包括PRAME和CD70导向的T细胞疗法）及其同种异体管线的权利。

Key Highlights:

重点：

Patient care continuity

病人护理连续性

: TECELRA will remain available to patients without interruption, now under USWM's stewardship.

：TECELRA 将继续在 USWM 的管理下不间断地提供给患者。

Future development

未来的发展

: USWM plans to bring lete–cel to the U.S. market, with potential regulatory approval anticipated in 2026, and will continue development of uza–cel in collaboration with Galapagos.

美国西部骨髓计划将把lete-cel带到美国市场，预计将在2026年获得潜在的监管批准，并且将继续与Galapagos合作开发uza-cel。

Employee transition

员工过渡

: Approximately half of Adaptimmune's U.S.-based workforce is being offered roles at USWM to support commercialization, production, and ongoing development of the acquired assets.

大约一半的 Adaptimmune 美国员工将被提供职位到 USWM，以支持所收购资产的商业化、生产和持续开发。

Transition support

过渡支持

: Adaptimmune is providing transition services through June 2026 to ensure operational continuity.

Adaptimmune 将通过 2026 年 6 月提供过渡服务，以确保运营的连续性。

Breck Jones

布雷克·琼斯

, Chief Executive Officer of US WorldMeds, commented: 'With the transaction now complete, we are excited to officially welcome Adaptimmune's programs and people into our organization. We are committed to building on the strong foundation Adaptimmune has established and advancing these therapies to bring lasting impact to patients with high unmet needs.'.

美国WorldMeds首席执行官评论道：“随着交易的完成，我们很高兴正式欢迎Adaptimmune的项目和人员加入我们的组织。我们致力于在Adaptimmune所建立的坚实基础上继续发展，并推进这些疗法，为那些具有高度未满足需求的患者带来持久的影响。”

TD Cowen acted as financial advisor, and Ropes & Gray LLP provided legal counsel, to Adaptimmune.

TD Cowen 担任财务顾问，Ropes & Gray LLP 则为 Adaptimmune 提供法律咨询。

Gibson, Dunn & Crutcher LLP provided legal counsel to US WorldMeds.

吉布森、邓恩和克拉彻律师事务所为美国WorldMeds公司提供了法律咨询。

The transaction was financed by debt financing led by funds managed by Oaktree Capital Management, L.P. ('Oaktree'), with participation from funds managed by Athyrium Capital Management, LP ('Athyrium').

该交易由橡树资本管理有限公司（“橡树”）管理的基金牵头的债务融资提供资金，参与方包括由Athyrium Capital Management, LP（“Athyrium”）管理的基金。

Indication

指示

TECELRA is a medicine, called a genetically modified autologous T cell immunotherapy, that is used to treat synovial sarcoma. It is used when other kinds of treatment do not work. TECELRA is different from other cancer medicines because it is made from your own white blood cells that are made to recognize and attack your cancer cells.

TECELRA是一种被称为基因修饰自体T细胞免疫疗法的药物，用于治疗滑膜肉瘤。当其他治疗方法无效时使用TECELRA。TECELRA不同于其他抗癌药物，因为它是由你自己的白细胞制成的，这些白细胞被设计为能够识别并攻击你的癌细胞。

Your healthcare provider will perform tests to see if TECELRA is right for you. TECELRA is approved based on patient response data. Additional data are needed to confirm the clinical benefit of TECELRA. It is not known if TECELRA is safe and effective in children..

您的医疗保健提供者将进行测试，以确定TECELRA是否适合您。TECELRA的批准是基于患者的反应数据。还需要更多数据来确认TECELRA的临床益处。目前尚不清楚TECELRA在儿童中是否安全有效。

Important Safety Information

重要安全信息

Important Warning: You will likely be in a hospital before and after getting TECELRA. TECELRA may cause side effects that can be severe or life-threatening. Call your healthcare provider or get emergency help right away if you get any of the following: fever (100.4°F/38°C or higher); chills/shivering; difficulty breathing; fast or irregular heartbeat; low blood pressure; fatigue; severe nausea, vomiting, or diarrhea; severe headache; or new skin rash.

重要警告：在使用TECELRA之前和之后，您可能需要住院。TECELRA可能会引起严重或危及生命的副作用。如果您出现以下任何症状，请立即致电您的医疗服务提供者或寻求紧急帮助：发烧（100.4°F/38°C或更高）；发冷/寒战；呼吸困难；心跳快速或不规则；低血压；极度疲劳；严重恶心、呕吐或腹泻；严重头痛；或新出现的皮肤皮疹。

Tell all your healthcare providers that you were treated with TECELRA..

告诉您所有的医疗保健提供者，您曾接受过TECELRA治疗。

After getting TECELRA, you will be monitored daily at the healthcare facility for at least 7 days after the infusion. You should plan to stay close to a healthcare facility for at least 4 weeks. Do not drive, operate heavy machinery, or do other activities that could be dangerous for at least 4 weeks after you get TECELRA.

在您接受TECELRA后，您将在医疗机构每天接受至少7天的监测。您应该计划在至少4周内靠近医疗机构。在接受TECELRA后的至少4周内，不要驾驶、操作重型机械或进行其他可能危险的活动。

Your healthcare provider will do blood tests to follow your progress. It is important that you have your blood tested. If you miss a scheduled appointment for your collection of blood, call your healthcare provider as soon as possible to reschedule..

您的医疗保健提供者将进行血液检查以跟踪您的进展。进行血液检查非常重要。如果您错过了预定的抽血预约，请尽快致电您的医疗保健提供者重新安排时间。

Before you receive TECELRA, tell your healthcare provider about all the medicines and supplements you take and your medical conditions, including: seizure, stroke, confusion, or memory loss; heart, liver, or kidney problems; low blood pressure; lung or breathing problems; recent or active infection; past infections that can be reactivated following treatment with TECELRA; low blood counts; pregnancy, you think you may be pregnant, or plan to become pregnant; breastfeeding; or taking a blood thinner..

在您接受TECELRA之前，告诉您的医疗保健提供者您正在服用的所有药物和补充剂以及您的健康状况，包括：癫痫、中风、意识模糊或记忆丧失；心脏、肝脏或肾脏问题；低血压；肺部或呼吸问题；近期或活动性感染；既往感染可能在接受TECELRA治疗后复发；血细胞计数低；怀孕、您认为自己可能怀孕或计划怀孕；正在哺乳；或正在服用血液稀释剂。

The most common side effects of TECELRA include nausea, vomiting, fatigue, infection, constipation, fever (100.4°F/38°C or higher), abdominal pain, difficulty breathing, decreased appetite, diarrhea, low blood pressure, back pain, fast heart rate, chest pain, general body swelling, low white blood cells, low red blood cells, and low platelets..

TECELRA最常见的副作用包括恶心、呕吐、疲劳、感染、便秘、发热（100.4°F/38°C或更高）、腹痛、呼吸困难、食欲减退、腹泻、低血压、背痛、心率加快、胸痛、全身肿胀、白细胞减少、红细胞减少和血小板减少。

You are encouraged to report side effects to the FDA at (800) FDA–1088 or

鼓励您向 FDA 报告副作用，电话：(800) FDA–1088 或

www.fda.gov/medwatch

。

Please see

请参见

Full Prescribing Information

完整处方信息

, including

，包括

Medication Guide

药品指南

, at

，在

Tecelra.com

特赛拉科技

。

About US WorldMeds

关于我们 WorldMeds

US WorldMeds is a U.S.-based pharmaceutical company focused on rare and specialty treatments. Our portfolio includes approved therapies for rare diseases and bleeding disorders, including approved therapies Iwilfin

美国WorldMeds是一家专注于罕见病和专科治疗的美国制药公司。我们的产品组合包括针对罕见病和出血性疾病的获批疗法，其中包括获批疗法Iwilfin。

an Revonto

撤销onto

. With this acquisition, we expand further into oncology and cell therapy, reinforcing our commitment to bringing life-changing therapies to patients.

通过此次收购，我们进一步扩展了在肿瘤学和细胞治疗领域的布局，重申了我们为患者带来改变生命疗法的承诺。

Media Contact:

媒体联系人:

Name:

名称：

Jessica Tracy

杰西卡·特雷西

Title: VP, Commercial Operations

标题：商业运营副总裁

US WorldMeds Ventures, LLC

美国环球医疗风险投资有限公司

Phone: